Amedisys Inc (NASDAQ:AMED) Insider Denise M. Bohnert Sells 362 Shares
Amedisys Inc (NASDAQ:AMED) insider Denise M. Bohnert sold 362 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $220.00, for a total transaction of $79,640.00. Following the completion of the transaction, the insider now owns 9,095 shares of the company’s stock, valued at approximately $2,000,900. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Amedisys stock opened at $234.16 on Friday. Amedisys Inc has a 12-month low of $121.00 and a 12-month high of $237.28. The stock has a market capitalization of $7.58 billion, a P/E ratio of 60.66, a P/E/G ratio of 3.44 and a beta of 0.95. The firm’s 50-day moving average is $202.10 and its two-hundred day moving average is $187.33. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.02 and a quick ratio of 1.48.
Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, July 28th. The health services provider reported $1.34 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.53. Amedisys had a net margin of 6.50% and a return on equity of 22.41%. The company had revenue of $485.06 million for the quarter, compared to analysts’ expectations of $468.38 million. During the same period last year, the company earned $1.21 EPS. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, analysts forecast that Amedisys Inc will post 4.82 EPS for the current year.
A number of equities analysts have recently issued reports on the stock. BidaskClub upgraded shares of Amedisys from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Jefferies Financial Group increased their price target on shares of Amedisys from $225.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday. UBS Group cut their price target on shares of Amedisys from $208.00 to $190.00 and set a “neutral” rating for the company in a report on Monday, May 11th. Royal Bank of Canada increased their price target on shares of Amedisys from $218.00 to $260.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Oppenheimer reiterated a “buy” rating and issued a $215.00 price target on shares of Amedisys in a report on Monday, April 27th. Five equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Amedisys has a consensus rating of “Buy” and a consensus price target of $215.67.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Further Reading: Sell-Side Analysts
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.